


7-19-01

88/1632  
#6

CASE 4-30583A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL813100786US  
Express Mail Label Number

July 19, 2001  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

IN RE APPLICATION OF

Art Unit: 1632

JUL 24 2001

AMLOT ET AL.

TECH CENTER 1600/2900

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF  
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6938

  
\_\_\_\_\_  
Susan Hess  
Attorney for Applicants  
Reg. No. 37,350

Date: July 18, 2001